Biotech Firm XOMA Faces Stock Challenges Amid Market Volatility XOMA's stock has dropped 25% in the past month, reaching a 52-week low of $20.87. Analysts remain optimistic, citing strong liquidity and a robust royalty portfolio. Recent acquisitions, including Pulmokine, are expected to drive future revenues, with price targets ranging from $55 to $104.435